Tiny RNA clues may explain bone disease differences
NCT ID NCT03838991
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
Fibrous dysplasia is a rare bone disease that causes pain, fractures, and deformities, but its severity varies widely for unknown reasons. This study looked at 24 adults—some with the disease and some without—to see if small molecules called microRNAs in blood and bone tissue are linked to how severe the disease is. The goal was to gather knowledge, not to test a treatment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- What this could lead to
- If successful, this could help explain why fibrous dysplasia affects people differently and point toward new ways to monitor or treat the disease.
- What could go wrong
- This is a small, observational study that does not test any treatment. It may not find clear links between microRNAs and disease severity, and any findings will need much more research to be useful.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for FIBROUS DYSPLASIA OF BONE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Service de Rhumatologie & INSERM U1033, Pavillon F, Hopital Edouard Herriot
Lyon, 69437, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.